Skip to main content
Top
Published in: Clinical Rheumatology 9/2007

01-09-2007 | Case Report

A case of limited cutaneous systemic sclerosis developing anti-mitochondria antibody positive primary biliary cirrhosis after acute myocardial infarction

Authors: Kiyomitsu Miyachi, Raleigh Hankins, Minoru Ihara, Akira Miyamoto, Tetsuroh Okano, Miwako Iwai, Katsuhiko Mikoshiba, Marvin J. Fritzler

Published in: Clinical Rheumatology | Issue 9/2007

Login to get access

Abstract

In this report, we present a 63-year-old woman who had limited cutaneous systemic sclerosis and subsequently developed typical primary biliary cirrhosis after an acute myocardial infarction. The patient initially developed Raynaud’s phenomenon, and 4 years later visited the clinic in 1994 complaining of abdominal distress, xerostomia, and xerophthalmia. A diagnosis of limited cutaneous systemic sclerosis was based on Raynaud’s phenomenon, sclerodactyly and anti-centromere antibodies. She was also found to have anti-inositol 1,4,5-trisphosphate receptor 3 (IP3R3) antibodies, but anti-mitochondrial antibodies were only weakly positive. Seven years later, she developed vertigo and nausea, and was hospitalized due to complaints of an oppressive sensation of the anterior chest. Electrocardiogram results showed a reduction of R waves and ST segment elevation in II, III, and aVf leads. Coronary angiography showed 99% obstruction of the left anterior descending artery and 50% of stenosis of the right coronary artery. Three years later, the patient was noted to have anti-mitochondrial antibodies. Retrospective analysis of the patient’s sera showed that IP3R3 antibodies were decreasing. Since myocardium is particularly rich in mitochondria, it is thought that myocardial infarction may have been the triggering event that initiated antigen-presenting cells to selectively induce an anti-mitochondrial antibody response.
Literature
1.
go back to reference Moroi Y, Peebles C, Fritzler MJ, Steigerwald J, Tan EM (1980) Autoantibody to centromere (kinetochore) in scleroderma sera. Proc Natl Acad Sci USA 77:1627–1631PubMedCrossRef Moroi Y, Peebles C, Fritzler MJ, Steigerwald J, Tan EM (1980) Autoantibody to centromere (kinetochore) in scleroderma sera. Proc Natl Acad Sci USA 77:1627–1631PubMedCrossRef
2.
go back to reference Makinen D, Fritzler MJ, Davis P, Sherlock S (1983) Anticentromere antibodies in primary biliary cirrhosis. Arthritis Rheum 26:914–917PubMedCrossRef Makinen D, Fritzler MJ, Davis P, Sherlock S (1983) Anticentromere antibodies in primary biliary cirrhosis. Arthritis Rheum 26:914–917PubMedCrossRef
3.
go back to reference Fritzler MJ, Manns MP (2002) Anti-mitochondrial antibodies. Clin Appl Immunol Rev 3:87–113CrossRef Fritzler MJ, Manns MP (2002) Anti-mitochondrial antibodies. Clin Appl Immunol Rev 3:87–113CrossRef
4.
go back to reference Iwai M, Tateishi Y, Hattori M, Mizutani A, Nakamura T, Futatsugi A et al (2005) Molecular cloning of mouse type 2 and type 3 inositol trisphospate receptors and identification of a novel type 2 receptor splice variant. J Biol Chem 18(280):10305–10317CrossRef Iwai M, Tateishi Y, Hattori M, Mizutani A, Nakamura T, Futatsugi A et al (2005) Molecular cloning of mouse type 2 and type 3 inositol trisphospate receptors and identification of a novel type 2 receptor splice variant. J Biol Chem 18(280):10305–10317CrossRef
5.
go back to reference Pillmer SR, Casiola-Rosen L, Baum BJ, Gelber AC (2004) Centromere protein C is a target of autoantibodies in Sjogren’s syndrome is uniformly associated with antibodies to Ro and La. J Rheumatol 31:1121–1125 Pillmer SR, Casiola-Rosen L, Baum BJ, Gelber AC (2004) Centromere protein C is a target of autoantibodies in Sjogren’s syndrome is uniformly associated with antibodies to Ro and La. J Rheumatol 31:1121–1125
6.
go back to reference Butler P, Hamilton-Miller J, Baum H, Burroughs AK (1995) Detection of M2 antibodies in patients with recurrent urinary tract infection using an ELISA and purified PBC specific antigens. Evidence for a molecular mimicry mechanism in the pathogens of primary biliary cirrhosis? Biochem Mol Biol Int 35:473–485PubMed Butler P, Hamilton-Miller J, Baum H, Burroughs AK (1995) Detection of M2 antibodies in patients with recurrent urinary tract infection using an ELISA and purified PBC specific antigens. Evidence for a molecular mimicry mechanism in the pathogens of primary biliary cirrhosis? Biochem Mol Biol Int 35:473–485PubMed
7.
go back to reference Hirakata M, Akizuki M, Miyachi K, Matsushima H, Okano T, Homma M (1988) Coexistence of CRERST syndrome and primary biliary cirrhosis. J Rheumatol 15:1166–1170PubMed Hirakata M, Akizuki M, Miyachi K, Matsushima H, Okano T, Homma M (1988) Coexistence of CRERST syndrome and primary biliary cirrhosis. J Rheumatol 15:1166–1170PubMed
8.
go back to reference Okano T, Hirakata M, Mimori T, Akizuki M (1989) Frequency of anti-centromere antibodies in the mitochondrial antibody positive sera. Rinsho Byori 37:1267–1272 Okano T, Hirakata M, Mimori T, Akizuki M (1989) Frequency of anti-centromere antibodies in the mitochondrial antibody positive sera. Rinsho Byori 37:1267–1272
9.
go back to reference Parveen S, Morshed SA, Nishioka M (1995) High prevalence of antibodies to recombinant CENP B in PBC: nuclear immunofluorescence pattern and ELISA reaction. J Gastroenterol Hepatol 10:438–445PubMed Parveen S, Morshed SA, Nishioka M (1995) High prevalence of antibodies to recombinant CENP B in PBC: nuclear immunofluorescence pattern and ELISA reaction. J Gastroenterol Hepatol 10:438–445PubMed
10.
go back to reference Whyte J, Hough D, Maddison PJ, McHugh NJ (1994) The association of primary biliary cirrhosis and systemic sclerosis is not accounted for by cross reactivity between mitochondrial and centromere antigen. J Autoimmun 71:413–424CrossRef Whyte J, Hough D, Maddison PJ, McHugh NJ (1994) The association of primary biliary cirrhosis and systemic sclerosis is not accounted for by cross reactivity between mitochondrial and centromere antigen. J Autoimmun 71:413–424CrossRef
11.
go back to reference Futatsugi A, Nakamura T, Yamada MK, Ebisui E, Nakamura K, Uchida K et al (2005) IP3Receptor types 2 and 3 mediate exocrine secretion underlying energy metabolism. Science 309:2232–2234PubMedCrossRef Futatsugi A, Nakamura T, Yamada MK, Ebisui E, Nakamura K, Uchida K et al (2005) IP3Receptor types 2 and 3 mediate exocrine secretion underlying energy metabolism. Science 309:2232–2234PubMedCrossRef
12.
go back to reference Wang H, Bloom O, Zhang M et al (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248–251PubMedCrossRef Wang H, Bloom O, Zhang M et al (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248–251PubMedCrossRef
Metadata
Title
A case of limited cutaneous systemic sclerosis developing anti-mitochondria antibody positive primary biliary cirrhosis after acute myocardial infarction
Authors
Kiyomitsu Miyachi
Raleigh Hankins
Minoru Ihara
Akira Miyamoto
Tetsuroh Okano
Miwako Iwai
Katsuhiko Mikoshiba
Marvin J. Fritzler
Publication date
01-09-2007
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 9/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-006-0465-1

Other articles of this Issue 9/2007

Clinical Rheumatology 9/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.